Literature DB >> 1676636

Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis.

L Waldhauser1, J Uetrecht.   

Abstract

Propylthiouracil (PTU) is associated with idiosyncratic agranulocytosis that may be due to reactive metabolites generated from oxidative metabolism by neutrophils. Therefore, the metabolism of PTU was investigated in activated neutrophils. Three oxidized metabolites were observed on HPLC: PTU-disulfide, propyluracil-2-sulfinate, and propyluracil-2-sulfonate (PTU-SO3-). No metabolism was detected in cells that had not been activated. Metabolism was inhibited by sodium azide and by catalase. The same products were produced by myeloperoxidase (MPO) in an MPO/H2O2/Cl- system. PTU inhibited its own metabolism; however, complete conversion to PTU-SO3- could be achieved with optimal PTU concentrations. MPO/H2O2 without Cl- produced only slight metabolism. The PTU-sulfenyl chloride is a postulated intermediate. In the absence of chloride, oxidation might proceed through propyluracil-2-sulfenic acid. The sulfenyl chloride and PTU-SO3- are both chemically reactive with sulfhydryl compounds such as N-acetylcysteine. Such reactive metabolites, generated by activated neutrophils, may be involved in hypersensitivity reactions associated with PTU, such as agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676636

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

Review 2.  Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.

Authors:  J P Uetrecht
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

3.  Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies.

Authors:  Wei-Ti Chen; Ching-Chi Chi
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

Review 4.  An overview on the proposed mechanisms of antithyroid drugs-induced liver injury.

Authors:  Reza Heidari; Hossein Niknahad; Akram Jamshidzadeh; Mohammad Ali Eghbal; Narges Abdoli
Journal:  Adv Pharm Bull       Date:  2015-03-05

Review 5.  Role of animal models in the study of drug-induced hypersensitivity reactions.

Authors:  Jack Uetrecht
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

Review 6.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

Review 7.  Possible implication of disordered neutrophil extracellular traps in the pathogenesis of MPO-ANCA-associated vasculitis.

Authors:  Daigo Nakazawa; Utano Tomaru; Akihiro Ishizu
Journal:  Clin Exp Nephrol       Date:  2012-12-06       Impact factor: 2.801

8.  Propylthiouracil increases sodium/iodide symporter gene expression and iodide uptake in rat thyroid cells in the absence of TSH.

Authors:  Mariko Sue; Takeshi Akama; Akira Kawashima; Hannah Nakamura; Takeshi Hara; Kazunari Tanigawa; Huhehasi Wu; Aya Yoshihara; Yuko Ishido; Naoki Hiroi; Gen Yoshino; Leonard D Kohn; Norihisa Ishii; Koichi Suzuki
Journal:  Thyroid       Date:  2012-08       Impact factor: 6.568

Review 9.  Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus.

Authors:  R L Rubin; A Kretz-Rommel
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

10.  Unusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case Report and Review of the Literature.

Authors:  Jun Yang; Jun Zhang; Qin Xu; Guo-Ping Sheng; Wan-Wen Weng; Meng-Jie Dong
Journal:  Int J Endocrinol       Date:  2015-04-28       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.